The use of anti-GITR antibody treatment in a murine model of glioblastoma multiforme by unknown
POSTER PRESENTATION Open Access
The use of anti-GITR antibody treatment in a
murine model of glioblastoma multiforme
Jason Miska1*, Alan L Chang1, Aida Rashidi2, Mahua Dey2, Yu Han1, Lingjiao Zhang2, Irina V Balyasnikova1,
Atique U Ahmed1, Maciej S Lesniak1
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer
(SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Glioblastoma multiforme (GBM), is the most common
adult brain tumor and despite many new therapies,
remains largely incurable. Regulatory T cells (Treg) are
highly immunosuppressive cells that accumulate within
glioma microenvironment, and reduction of their function
or trafficking has been previously shown to enhance survi-
val in pre-clinical models of GBM. One of the principal
mechanisms of Treg suppression in vitro is that they must
have direct contact with their targets; a modality recently
appreciated in vivo. It is thought that Tregs utilize the
cytotoxic proteins perforin and granzyme to directly lyse
target immune cells. While this might be a major effector
in preventing the anti-tumor response, little has been stu-
died on the importance this pathway is in the context of
glioma.
An agonistic antibody against GITR (glucocorticoid
induced TNF family receptor) has been demonstrated to
negatively influence Tregs in a number of animal models.
However, the role of this therapy in GBM has not yet been
explored. We hypothesized that anti-GITR treatment sup-
presses granzyme expression by Tregs, which results in
stronger anti-tumor immune responses against glioma.
Using the GL261 murine model of GBM, 4 × 105 cells
were stereotactically injected in the right hemisphere of
6-8 week old mice. Mice received anti-GITR or its isotype
control directly into the tumor site (2ug) or i.p. (500ug) at
both 9 and 14 days post implantation Mice were separately
assessed for survival, and flow cytometric analyses were
performed to determine the influence of the antibody on
immune response in the brain.
Analysis revealed that many Tregs specifically within
tumor tissue express granzyme B, which increases over
time. Animals treated with anti-GITR antibody caused a
significant increase in animal survival only when injected
directly into the tumor site, while peripheral treatment
only had a modest effect. Antibody treatment caused a sig-
nificant decrease in granzyme B+ Tregs with peripheral
treatment. However, with intratumoral treatment, we saw
both a decrease in granzyme expression and Treg number.
Our data suggests that within the glioma microenvir-
onment, Tregs gain the ability to produce granzyme B,
which can be suppressed by administration of anti-
GITR antibody treatment, but this mechanism is not
alone sufficient to enhance animal survival. However,
intratumoral anti-GITR treatment dramatically reduced
Tregs and their granzyme B expression, suggesting
another mechanism in this therapeutic modality. This
study shows that the site of anti-GITR administration
could be critical in its efficacy when taken into the
clinic.
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